273.23
BATS BZX Real-Time Price
As of 12:54pm ET
 +4.25 / +1.58%
Today’s Change
114.41
Today|||52-Week Range
275.46
+64.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$24.8B

Company Description

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Contact Information

BeiGene Ltd.
Zhongguancun Life Science Park
Beijing Beijing 102206
P:861058958000
Investor Relations:

Employees

Shareholders

Other institutional37.42%
Mutual fund holders21.24%
Individual stakeholders21.09%

Top Executives

John V. OylerChairman & Chief Executive Officer
Xiao Bin WuPresident & General Manager-China Region
Howard LiangChief Financial & Strategy Officer
Jane E. HuangChief Medical Officer-Hematology
Yong BenChief Medical Officer-Immuno & Oncology Department